Recent advances in intraocular drug delivery systems

Area of Science:

• Ophthalmology
• Pharmacology
• Biomedical Engineering

Background:

• Vitreoretinal diseases pose treatment challenges due to the eye's protective barriers limiting drug penetration.
• Topical and systemic drug delivery methods are often ineffective for reaching the retina and vitreous.
• The unique ocular environment restricts drug diffusion, necessitating specialized delivery strategies.

Purpose of the Study:

• To review recent advances in intraocular drug delivery systems (DDS) for treating eye diseases.
• To discuss the development of novel DDS for improved drug efficacy and reduced administration frequency.
• To explore patent literature on biodegradable and non-biodegradable implants and targeted drug delivery.

Main Methods:

• Review of clinical studies and patent literature on intraocular drug delivery systems.
• Analysis of various DDS approaches, including implants, inserts, injections, and targeted therapies.
• Discussion of controlled-release mechanisms and drug targeting strategies for ocular administration.

Main Results:

• Successful clinical applications of non-biodegradable and biodegradable implants/inserts for ocular drug delivery.
• Efficacy of intravitreal injections of triamcinolone acetonide and anti-vascular endothelial growth factor (anti-VEGF) therapies.
• Emerging treatments for exudative age-related macular degeneration and macular edema utilizing advanced DDS.

Conclusions:

• Intraocular DDS have significantly improved drug delivery to the eye, overcoming previous limitations.
• Future DDS development is crucial for novel treatment modalities and enhancing current therapies.
• Controlled release and drug targeting represent key strategies for optimizing ocular drug delivery and patient outcomes.